isco.ob - a new approach to developing stem cell therapy
TRANSCRIPT
-
8/4/2019 ISCO.OB - A New Approach to Developing Stem Cell Therapy
1/17
1
(ISCO.OB)
A New Approach to DevelopingStem Cell Therapy
-
8/4/2019 ISCO.OB - A New Approach to Developing Stem Cell Therapy
2/17
Statements pertaining to anticipated technological developments andtherapeutic applications, the potential benefits of collaborations,affiliations, and other opportunities for the company and its subsidiaries,along with other statements about the future expectations, beliefs, goals,plans, or prospects expressed by management constitute forward-lookingstatements. Any statements that are not historical fact (including, but notlimited to statements that contain words such as "will," "should,"
"believes," "plans," "anticipates," "expects," "estimates,") should also beconsidered to be forward-looking statements. Forward-looking statementsinvolve risks and uncertainties, including, without limitation, risks inherentin the development and/or commercialization of potential products,uncertainty in the results of clinical trials or regulatory approvals, need andability to obtain future capital, application of capital resources among
competing uses, and maintenance of intellectual property rights. Actualresults may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with themany uncertainties that affect the company's business, particularly thosementioned in the cautionary statements found in the company's Securitiesand Exchange Commission filings. The company disclaims any intent orobligation to update these forward-looking statements.
2
Forward-looking statements
-
8/4/2019 ISCO.OB - A New Approach to Developing Stem Cell Therapy
3/17
ISCO.OB
3
Common shares outstanding: 76 million
Public float: 69.4 million
Share price (recent): 0.94 (12 months: $0.67 - $2.37)
Market capitalization: ~$72 million
2010 revenue: $1.6 million
Q-2 2011 revenue $ 1.1 million
$25 million equity capital committed if needed
-
8/4/2019 ISCO.OB - A New Approach to Developing Stem Cell Therapy
4/17
Our Goal: Build a Billion DollarCompany
4
1. Control The IP
2. Pick Big Markets
3. Create a Revenue Base
4. Build the Right Team
5. Put it All Together
-
8/4/2019 ISCO.OB - A New Approach to Developing Stem Cell Therapy
5/17
The IP
5
1. Parthenogenesis: a Unique Technology
2. We Own It
3. Changes the Whole Business Model
-
8/4/2019 ISCO.OB - A New Approach to Developing Stem Cell Therapy
6/17
6
Why Parthenogenesis Matters
hpSCs Embryonic iPS Adult SCsEthics(Relative to destruction ofviable human embryos)
No viableembryo
Destroysviable embryo
No embryo No embryo
Immune matchingand cell banking(practical source of cells)
Matchesmillions ofpatients
Matchesdonor only.
Matchesdonor only
Matchesdonor only
Pluripotency(Become cells from all partsof body)
Yes Yes Yes No
Proliferation(Ease of expansion inculture)
Strong Strong Strong Weak
Genetic
Manipulation(Restructuring of geneexpression patterns)
Minimal Minimal Substantial Minimal
Application forDiseases withGeneticComponent
Superior SuperiorDeficient
(carry damagedgene)
Deficient(carry damaged
gene)
-
8/4/2019 ISCO.OB - A New Approach to Developing Stem Cell Therapy
7/177
Big Markets
Cornea: Pre-clinical trials
10 million corneal blindness cases worldwide
Toxicity testing: $1billion secondary market
Retina: Pre-clinical trials
AMD: 1.75 million US Patients
Retinitis pigmentosa (RP): 100,000 US Patients
Liver: Successful pre-clinical engraftment; newway to create pure cell population discovered
30,000 deaths/year in the US
15,750 on transplant waiting list
Neurological Diseases: Pre-clinical trials
Parkinsons, Alzheimers, etc)
Each a huge Market
-
8/4/2019 ISCO.OB - A New Approach to Developing Stem Cell Therapy
8/17
Universal Stem Cell Banking
Every person has an immune type
There are 200 common types in a typical populationParthenogenetic stem cells: Can be matched to millions of people Example: 5 cell lines could match 42 million in the USA
A Bank of these could provide immune-matched cellsfor millions at a cost they could afford
For the Scientist
-
8/4/2019 ISCO.OB - A New Approach to Developing Stem Cell Therapy
9/17
Revenue Sources
9
1. Skin Care
2. Research Products
3. Embedded Technology
-
8/4/2019 ISCO.OB - A New Approach to Developing Stem Cell Therapy
10/17
Development Built from ISCO Cells Clinically tested for safety and efficacy
Commercialization
Direct-to-consumer; physicians and spas $1.1 million sales in first launch Could solve cash flow issues for whole Company
10
Baseline 6 weeks 16 weeks
Lifeline Skin Care
-
8/4/2019 ISCO.OB - A New Approach to Developing Stem Cell Therapy
11/17
Biomedical Products
>130 products: growth factors, media and human cells More new products in 2009-10 than the market-leader cGMP media and cell manufacturing capacity
Distribution
Direct sales (USA) International distributors: Europe, Asia (incl.India)
OEM partners: ATCC, Millipore, Life Technologies
11
-
8/4/2019 ISCO.OB - A New Approach to Developing Stem Cell Therapy
12/17
Thread-based vascular graft(off the shelf, allogeneic)
Addressable market: 500,000 patients
Revenue > $100 Million/year
Embedded Technology--Example
Confidenti
-
8/4/2019 ISCO.OB - A New Approach to Developing Stem Cell Therapy
13/17
Executive Team
Kenneth Aldrich, Esq., Executive Chairman
30 years investment in and management of public and private companiesAndrey Semechkin, Ph.D., CEO
Member of Russian Academy of Sciences Successful founder and manager of international companies
Jeffrey Janus, SVP and CEO Lifeline Cell Technology
25 years experience with cell-based and FDA-compliant biological products Founder of Clonetics (now research product market leader Lonza)
Ruslan Semechkin, Ph.D., VP and CEO Lifeline Skin Care
Medical science and cosmeceutical development experience
Kurt May, Sr. VP GTE, Price Smart, Psynomics, University of San Diego
Simon Craw, Ph.D., VP
Executive with Merck, AstraZeneca and Novartis 22 years scientific operational experience
13
-
8/4/2019 ISCO.OB - A New Approach to Developing Stem Cell Therapy
14/17
Putting It All Together
14
Parthenogenetic
Stem Cells
LifelineBioresearch
Products
Stem Cell Bank
LifelineSkin Care
Products
Therapeutic
Development
Partnering
-
8/4/2019 ISCO.OB - A New Approach to Developing Stem Cell Therapy
15/17
Investment Highlights
15
Better than embryonic stem cellsPatented
Technology Proven
Stem Cell Bank
Manufacturing capacity and know-how in place
Cash flow today
Viable international business model
-
8/4/2019 ISCO.OB - A New Approach to Developing Stem Cell Therapy
16/17
Whats Next for 2012?
16
1. Continued Expansion Stem Cell Bank
2. First Customers for Toxicity Testing
3. Increased Skin Care Sales
4. Increased Sales in Lifeline CellTechnology
5. New Scientific Findings6. Possible Start of Clinical Trials
a. Liverb. Cornea
c. Retina
-
8/4/2019 ISCO.OB - A New Approach to Developing Stem Cell Therapy
17/1717
Contact information
www.internationalstemcell.com
Kenneth Aldrich, Chairman760-940-6383
mailto:[email protected]:[email protected]